Literature DB >> 24345353

Are selective estrogen receptor modulators (SERMs) a therapeutic option for HPV-associated cervical lesions and cancers?

Karl Munger1.   

Abstract

This Commentary highlights the article by Spurgeon et al which evaluates oral SERM raloxifene as a potential therapeutic agent for HPV-associated cancer.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24345353     DOI： 10.1016/j.ajpath.2013.11.005

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


  3 in total

1.  SERMs suppresses the growth of ERα positive cervical cancer xenografts through predominant inhibition of extra-nuclear ERα expression.

Authors:  Balaji Ramachandran; Kanchan Murhekar; Shirley Sundersingh
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

2.  Antiestrogen use reduces risk of cervical neoplasia in breast cancer patients: a population-based study.

Authors:  Chia-Jung Hsieh; Mun-Kun Hong; Pau-Chung Chen; Jen-Hung Wang; Tang-Yuan Chu
Journal:  Oncotarget       Date:  2017-04-25

3.  Estrogen Attenuates the Growth of Human Papillomavirus-Positive Epithelial Cells.

Authors:  Molly L Bristol; Claire D James; Xu Wang; Christian T Fontan; Iain M Morgan
Journal:  mSphere       Date:  2020-03-18       Impact factor: 4.389
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.